Ex vivo expansion of hematopoietic cells and their clinical use

Haematologica

Volumn 83, Issue 9, 1998, Pages 824-848

  Aglietta, Massimo ^a   Bertolini, Francesco ^b   Carlo Stella, Carmelo ^c   De Vincentiis, Armando ^d   Lanata, Luigi ^e   Lemoli, Roberto M ^f   Olivieri, Attilio ^g   Siena, Salvatore ^h   Zanon, Paola ^e   Tura, Sante ^f,i  

^a UNIVERSITY OF TURIN   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Chemistry Section   (Italy)

^e Amgen Italia SpA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allogeneic transplantation; Bone marrow; Cord blood; Dendritic cells; Hematopoietic stem cells; Peripheral blood

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMING UNIT GM; CYTOKINE PRODUCTION; CYTOTOXIC LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; NATURAL KILLER CELL; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL SEPARATION; CELLS, CULTURED; DENDRITIC CELLS; FORECASTING; HEMATOPOIESIS; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MICE; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 17044459521     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (215)

1. Scott MA, Gordon MY. In search of the haemopoietic stem cell. Br J Haematol 1995; 90:738-43.
2. Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell 1997; 88:287-98.
3. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989; 339:27-30.
4. Lajtha LG. Haemopoietic stem cells. Br J Haematol 1975;29:529-35.
5. McCulloch EA. Control of hematopoiesis at the cellular level. In: Gordon AS, ed. Regulation of hematopoiesis (vol. 1). New York: Appleton, 1970. p 133-54.
6. Gordon MY. Physiological mechanisms in BMT and haemopoiesis - revisited. Bone Marrow Transplant 1993; 11:193-7.
7. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110:1001-20.
8. Verdi JM, Schmandt R, Bashirullah A, et al. Mammalian numb is an evolutionary conserved signaling adapter protein that specifies cell fate. Curr Biol 1996; 6:1134-45.
9. Zhong WM, Feder JN, Jiang MM, Jan LY, Jan YN. Asymmetric localization of a mammalian numb homolog during mouse cortical neurogenesis. Neuron 1996; 17:43-53.
10. Mayani H, Dragowska W, Lansdorp PM. Lineage commitment in human hemopoiesis involves asymmetric cell division of multipotent progenitors and does not appear to be influenced by cytokines. J Cell Physiol 1993; 157:576-9.
11. Till JE, McCulloch EA, Siminovitch L. A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells. Proc Natl Acad Sci USA 1964; 51:29-33.
12. Trentin JJ. Influence of hematopoietic organ stroma (hematopoietic inductive microenvironments) on stem cell differentiation. In: Gordon AS. ed. Regulation of Hematopoiesis. vol. 1. New York: Appleton, 1970. p. 161-85.
13. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81:2844-53.
14. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993; 82:3515-23.
15. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homologue of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66:649-61.
16. Seydoux G, Mello CC, Pettitt J, Wood WB, Priess JR, Fire A. Repression of gene expression in the embryonic germ lineage of C. elegans. Nature 1996; 382:713-6.
17. Metcalf D. Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. Proc Natl Acad Sci USA 1991; 88:11310-4.
18. Pawson T. Protein modules and signalling networks. Nature 1995; 373:573-80
19. Bedi A, Sharkis SJ. Mechanisms of cell commitment in myeloid cell differentiation. Curr Opin Hematol 1995; 2:12-21.
20. Williamson EA, Boswell SH. Signal transduction during myeloid cell differentiation. Curr Opin Hematol 1995; 2:29-40.
21. Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Gens Dev 1995; 9:1753-65.
22. Sauvageau G, Thorsteinsdottir U, Hough MR, et al. Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. Immunity 1997; 6:13-22.
23. Wessely O, Deiner E-M, Beug H, von Lindern M. The gluocorticoid receptor is a key regulator of the decision between self-renewal and differentiation in erythroid progenitors. EMBO J 1997; 16:267-80.
24. Dotti GP, Carlo-Stella C, Spinelli O, et al. Shc overexpression induces selective hypersensitivity to GM-CSF and prevents apoptosis of the GM-CSF-dependent acute myelogenous leukemia cell line GF-D8. In: Hematology and blood transfusion. New York: Springer-Verlag, 1997. In press.
25. Rossi F, McNagny KM, Smith G, Frampton J, Graf T. Lineage commitment of transformed haematopoietic progenitors is determined by the level of PKC activity. EMBO J 1996; 15:1894-901.
26. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91:9857-60.
27. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1994; 11:35-71.
28. Carlo-Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical relevance. Haematologica 1995; 80:367-87.
29. Krause DS, Fackler MJ, Civin CI, Stratford May W. CD34: structure, biology, and clinical utility. Blood 1996; 87:1-13.
30. Civin CI, Gore SD. Antigenic analysis of hematopoiesis: a review. J Hematother 1993; 2:137-44.
31. Baumhueter S, Singer MS, Henzel W, et al. Binding of L-selectin to the vascular sialomucin CD34. Science 1993; 262:436-41.
32. high cells. Blood 1993; 82:3283-9.
33. Small D, Levenstein M, Kim E, et al. STK-1, the human homologue of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91:459-63.
34. Zanjani ED, Almeida-Porada G, Leary AG, Ogawa M. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression including giving rise to CD34+ cells. Blood 1997; 90:252a.
35. Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive hematopoietic cells capable of repopulating NOD/SCID mice: implications for gene therapy. Nature Med 1996; 2:1329-37.
36. Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immunodeficient mice. Proc Natl Acad Sci USA 1997; 94:5320-5.
37. Eaves CJ, Cashman JD, Eaves AC. Methodology of long-term culture of human hematopoietic cells. J Tiss Cult Methods 1991; 13:55-62.
38. Sutherland HJ, Eaves CJ, Eaves AJ, Dragowskas W, Lansdorp PM. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989; 74:1563-70.
39. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 1996; 93:1470-4.
40. Breems DA, Blokland EAW, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994; 8:1095-104.
41. Gordon MY, Amos TAS. Stochastic effects in hemopoiesis. Stem Cells 1994; 12:175-9.
42. Briddell RA, Kern BP, Zilm KL, Stoney GB, McNiece IK. Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J Hematother 1997; 6:145-50.
43. Haylock D, Simmons P, To LB, Juttner C. Growth factors and ex vivo expansion of hemopoietic progenitor cells. In: Morstyn G, Sheridan W. eds. Cell Therapy. Cambridge: Cambridge University Press, 1996. p. 221-37.
44. Alcorn MJ, Holyoake TL, Richmond L, et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996; 14:1839-47.
45. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex-vivo. N EnglJ Med 1995; 333:283-7.
46. Lemoli RM, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996; 87:1625-32.
47. Gazitt Y, Reading C, Hoffman R, et al. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86:381-9.
48. Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood 1996; 88:1796-804.
49. Fogli M, Amabile M, Martinelli G, et al. Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. Br J Haematol 1998; 101:119-29.
50. Peters D, Branscomb E, Dean P, et al. The LLNL high-speed sorter: design, features, operational characteristics and biological utility. Cytometry 1985; 6:290-301.
51. Tsukamoto A, Sasaki D, Chen BP, Hoffman R. Characterization and isolation of mobilized peripheral blood stem cells using a high-speed cell sorter. In: Morstyn G, Sheridan W, eds. Cell Therapy. Cambridge: Cambridge University Press, 1996. p. 183-98.
52. Okarma T, Lebkowski J, Schain L, et al. The AIS collector: a new technique for stem cell purification. In: Worthington-White DA, Gee AP, Gross S, eds. Advances in bone marrow purging and processing. New York: Wiley Liss, 1992. p. 449-59.
53. Kemshead JT, Ugelstad J. Magnetic separation techniques: their application to medicine. Mol Cell Biochem 1985; 67:11-8.
54. Kvalheim G, Sorensen O, Fodstad O, et al. Immunomagnetic removal of B-lymphoma cells from human bone marrow: A procedure for clinical use. Bone Marrow Transpl 1988; 3:31-41.
55. Civin CI, Strauss LC, Facker MJ, Trismann TM, Wiley JM, Loken RL. Positive stem cell selection. Basic science. In: Gross S, Gee A, Worthington-White DA, eds. Bone marrow purging and processing. New York. Wiley-Liss, 1990. p. 387-402.
56. Milteny S, Mueller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990; 11:231-8.
57. Lemoli RM, Tafuri A, Fortuna A, et al. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997; 89:1189-96.
58. Link H, Arseniev L, Bahre O, et al. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 1995; 86:2500-8.
59. Koller MR, Emerson SG, Palsson BO. Large scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 1993; 82:378-84.
60. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16:437-40.
61. Moore MAS: Expansion of myeloid stem cells in culture. Semin Hematol 1995; 32:183-92.
62. Emerson GE. Ex vivo expansion of hematopoietic precursors, progenitors and stem cells: the next generation of cellular therapeutics. Blood 1996; 87:3082-8.
63. Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci USA 1995; 93:4040-4.
64. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ. Ex vivo expansion of murine marrow cells with IL-3, IL-6, IL-11 and SCF leads to impaired engraftment in irradiated hosts. Blood 1996; 87:30-7.
65. Traycoff CM, Cornetta K, Yoder MC, Davidson A, Srour EF. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of cells possessing, different levels of bone marrow repopulating potential. Exp Hematol 1990; 24:299-306.
66. Young JC, Varma A, DiGiusto D, Backer MP. Retention of quiescent hematopoietic cells with high proliferative potential during ex vivo stem cell culture. Blood 1996; 87:545-56.
67. Di Giusto DL, Lee R, Moon K, et al. Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 1996; 87:1261-71.
68. Gabutti V, Foà R, Mussa F, Aglietta M. Behaviour of human haematopoietic stem cells in cord and neonatal blood. Haematologica 1975; 60:4.
69. Lansdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med 1993; 178:787-91.
70. Zandstra PW, Eaves CJ, Piret JM. Expansion of hematopoietic progenitor cell populations in stirred suspension bioreactors of normal human bone marrow cells. Biotechnology 1994; 12:909-14.
71. Bertolini F, Battaglia M, Corsini C, et al. Engineered stromal layers and continuous flow culture enhance multidrug resistance gene transfer in hematopoietic progenitors. Cancer Res 1996; 56:2566-72.
72. Keller JR, Bartelmez SH, Sitnicka E, et al. Distinct and overlapping direct effects of macrophage inflammatory protein 1α and transforming growth factor-β on hematopoietic progenitor/stem cell growth. Blood 1994; 84:2175-81.
73. + human progenitors. Exp Hematol 1997; 24:1509-15.
74. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hemopoietic stem cell-enriched populations. Cell 1991; 65:1143-52.
75. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Blood 1996; 87:3563-70.
76. Piacibello W, Fubini L, Sanavio F, et al. Effect of human FLT3 ligand on myeloid leukemia cells growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1995; 86:4105-14.
77. Piacibello W, Garetto L, Sanavio F, et al. The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. Exp Hematol 1996; 24:340-6.
78. Bertolini F, Battaglia M, Pedrazzoli P, et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997; 89:2679-88.
79. Petzer AI, Zandstra PW, Piret JM, Eaves CJ. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: Novel responses to Flt3-ligand and thrombopoietin. J Exp Med 1996; 183:2551-8.
80. Yonemura Y, Ku H, Lyman SD, Ogawa M. In vitro expansion of hematopoietic progenitors and maintenance ot stem cells: comparison between FLT3/FLK-2 ligand and Kit ligand. Blood 1997; 89:1915-21.
81. Moore TA, Zlotnik A. Differential effects of Flk2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells. J Immunol 1997; 158:4187-92.
82. Dao MA, Hannum CH, Kohn DB, Nolta JA. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral mediated transduction. Blood 1997; 89:446-56.
83. Zandstra PW, Conneally E, Petzer AL, Piret JM, Eaves CJ. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci USA 1997; 94:4698-703.
84. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86:419-31.
85. Kaushanski K, Broudy VC, Lin N, et al. Thrombopoietin, the mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92:3234-38.
86. Goncalves F, Lacout O, Villeval JL, Wendung F, Vainchenker W, Dumenil D. Thrombopoietin does not induce lineage-restricted commitment of MpI-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation. Blood 1997; 89:3544-53.
87. Ramsfjell V, Borge OJ, Cui L, Jacobsen SEW. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+CD38-) human bone marrow progenitor cells. J Immunol 1997; 158:5169-77.
88. Ku H, Hirayama F, Kato I, et al. Soluble thrombopoietin receptor and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for Flt3/Flk2. Blood 1996; 88:4124-31.
89. Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89:2644-53.
90. Uchida N, Aguila HL, Fleming WH, Jerahek I, Weissman IL. Rapid and sustained hematopoietic recover in lethally irradiated mice transplanted with purified Thy1.Low, Lin-Sca-1+ hematopoietic stem cells. Blood 1994; 83:3758-79.
91. Szilvassy SJ, et al. Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells. Blood 1996; 88:3642-53.
92. Williams SF, Lee WJ, Bender JG, et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87:1687-91.
93. + lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progeritor cells. Blood 1996; 88:3166-75.
94. Vogel W, Behringer D, Scheding S, Kanz L, Brugger W. Ex vivo expansion of CD34+ peripheral blood progenitor cells: Implications for the expansion of contaminating epithelial tumor cells. Blood 1996; 88:2707-13.
95. th ed. Am Soc Microbiol Washington D.C., 1992. p. 220-30.
96. + T lymphocytes. J Immunol 1989; 142:1325-32.
97. Kagi D, Vignaux F, Ledermann B, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994, 265:528-30.
98. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995, 166:236-46.
99. Braun MY, Lowin B, French L, Acha Orbea H, Tschopp J. Cytotoxic T cell deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft versus host disease. J Exp Med 1996, 183:657-61.
100. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1 (CD-95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156:13-7.
101. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996; 17:86-92.
102. Kanegane H, Tosato G. Activation of naive and memory T cells by Interleukin-15. Blood 1996; 88:230-5.
103. Richard C, Alsar MJ, Calavia J, et al. Recombinant human GM-CSF enhances T cell mediated cytotoxic function after ABMT for hematological malignancies. Bone Marrow Trasplant, 1993; 11:473-8.
104. Bendall LJ, Kortlepel, Gottlieb DJ. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Leukemia 1995; 9:677-84.
105. Cantori I, Olivieri A, Rupoli S, et al. The association of IL-2 plus GM-CSF has protective effects and reduces the apoptosis in liquid culture. Blood 1996; 88:112a.
106. Trinchieri G. Interleukin-12: a cytokine produced by antigen presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84:4008-27.
107. Gerosa F, Paganin C, Peritt D, et al. Intereleukin-12 primes human CD4 and CD 8 T cell clones for high production of both interferon-γ and interleukin-10. J Exp Med 1996,183:2559-69.
108. Abdul-Hai A, Or R, Slavis S, et al. Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice. Exp Hematol, 1996; 24:1416-22.
109. Mavroudis D, Barret J. The graft-versus-leukemia effect. Current Opinion Hematol 1996: 3:423-29.
110. Glass B, Unarek L, Zeis M, et al. Graft-versus-leukemia activity can be predicted by natural cytotoxicity against leukemia cells. Br J Haematol 1996; 93:412-20.
111. Goldman JM., Gale RP., Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T cell depletion. Ann Intern Med 1988; 108:806-14.
112. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995; 86:2041-50.
113. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide. Blood, 1997; 89:2203-9.
114. Hokland M, Jacobsen N, Ellegaard J, Hokland P. Natural killer function following allogeneic bone marrow transplantation. Transplantation 1988; 45:1080-4.
115. Bengtsson M, Totterman TH, Smedmyr B, Festin R, Simonseen B. Regeneration of functional and activated N K and T subset cells in the marrow and blood after autologous bone marrow transplantation. A prospective phenotypic study with 2/3-color FACS analysis. Leukemia 1989; 3:68-75.
116. Jorgensen H, Hokland P, Jensen T, Basse P, Hokland M. Natural killer cell in peripheral blood after autologous bone marrow transplantation. Nature Immun 1995; 14:164-72.
117. th Novo Nordisk Foundation Symposium "Leukocyte adhesion" 1992. p. 353-60.
118. + NK progenitor. Blood 1994; 83:2594-601.
119. + hematopoietic progenitor cells. Blood 1996; 87:2632-40.
120. +dim natural killer cells in patients with chronic myelogenous leukemia progessively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996; 88:2279-87.
121. Daniels B, Daniels B, Karlhofer FM, Seaman WE, Yokoama W. A natural killer cell receptor specific for a major histocompatibility complex class I molecule. J Exp Med 1994; 180:687-92.
122. Moretta A, Vitale M, Sivori S, et al. Human natural killer cell receptors for HLA-class I molecules. Evidence that the kp43 (CD94) molecule functions as receptor for HLA-B alleles. J Exp Med 1994; 180:545-55.
123. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97.
124. Parrado A, Rodriguez-Fernadez JM, Casares S, et al. Generation of LAK cells in vitro in patients with acute leukemia. Leukemia 1993; 7:1344-8.
125. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995; 86:1619-28.
126. Klingemann HG, Deal H, Reid D, Eaves CJ. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Haematol 1993; 21:1263-70.
127. Koo GC, Peppard JR, Latime EC. Characterization of cytotoxic cells generated from bone marrow culture. Cell Immunol 1986; 98:172-80.
128. Silva MRG, Hoffman R, Srour EF, Ascensao JL. Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. Blood 1994; 84:841-6.
129. + CD33- bone marrow progenitors. J Immunol 1993; 150:5263-9.
130. Miller JS, Verfaule C, McGlave PB. The generation of human natural killer cells from CD34+/DR•- primitive progenitors in long-term bone marrow culture. Blood 1992; 80:2182-7.
131. Silva MRG, Parreira A, Ascensao JL. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp Hematol, 1995; 23:1676-81.
132. Miller JS, Prosper F, MC Cullar V. Natural Killer cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 1997; 90:3098-105.
133. Hercend T, Farace F, Baume D, et al. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol 1990; 9:546-55.
134. Beaujean F, Bernaudin F, Kuentz M, et al. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 15:691-6.
135. Wong EK, Eaves C, Klingemann HG. Comparison of natural killer activity of human bone marrow and blood cells in culture containing IL-2, IL-7 and 1L-12. Bone Marrow Transplant 1996; 18:63-71.
136. Miller JS, Klingsporn S, Lund J, et al. Large-scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 1994; 14: 555-62.
137. Pierson BA, Europa AF, Hu WS, Miller JF. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor. J Hematother 1996; 5:475-83.
138. Vujanovic NL, Yasumura S, Hirabayashi H, et al. Antitumor activities of human IL-2 activated natural killer cells in solid tumor tissues. J Immunol 1995; 154:281-9.
139. Lanier LL, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480-6.
140. Schmidt-Wolf IGH, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. propagation of large numbers of T cells with natural killer cell markers. B J Haematol 1994; 87:453-8.
141. Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 1995; 15:33-9.
142. Slavin S, Ackerstein A, Weiss L, Nagler A, Reuven O, Naparstek E. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992; 10:221-7.
143. Glass B, Uhrek L, Zeis M, Loefler H, Mueller-Ruchholtz W, Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 1996; 93:412-20.
144. Rocha M, Umansky V, Lee KH, Hacker HJ, Benner A, Schirrmacher V. Difference between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or Host cells. Blood 1997; 89:2189-202.
145. Van der Harst D, Goulmy E, Falkenburg JHF, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83:1060-6.
146. Hoffmann T, Theobald M, Bunjes D, Weiss M, Heimpel H, Heit W. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993; 12:1-8.
147. Kolb HJ, Mittermueller J, Clemm CH, et al. Donor leukocyte trasfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76:2462-5.
148. Champlin R. Separation of graft-vs.-host disease and graft-vs-leukemia effect against chronic myelogenous leukemia. Exp Hematol 1995; 23:1148-51.
149. Datta AR, Barrett AJ Jang YZ, et al. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14:517-24.
150. Oettel KR, Wesly OH, Albertini MR, et al. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient. Blood 1994; 83:3390-402.
151. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2:52-8.
152. Rooney CM, Smith CA, Loftin S, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9-13.
153. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogenic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
154. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87:2195-204.
155. Weiner GJ, De Gast GC. Bispecific monoclonal antibody therapy of b-cell malignancy. Leuk Lymphoma 1995; 16:199-207.
156. Disis ML, Bernhard H, Shiota FM, et al. Granulocyte macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88:202-10.
157. Faber LM, Van Luxemburg-Heijs SAP, Veenhof WFJ, Willemze R, Falkenburg JHF. Generation of CD4+ cytotoxic T-lymphocyte clones from patient with severe graft-versus-host disease after allogenic bone marrow transplantation: implication for graft-versus-leukemia reactivity. Blood 1995; 86:2821-8.
158. Bonini C, Verzelletti S, Servida P, et al. Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after alloBMT. Blood 1994; 84:110a.
159. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996; 24:859-62.
160. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 260:937-44.
161. Wong J. Dendritic cells reach out to the clinic. Nature Med 1997; 3:129.
162. Young JW, Inaba K. Dendritic as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996; 183:7-11.
163. Reid CDL. The dendritic cell lineage in haemopoiesis. BrJ Haematol 1997; 96:217-33.
164. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3:459-73.
165. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996; 183:1287-92.
166. Gluckman JC, Canque B, Chapuis F, Rosenzwajg. In vitro generation of human dendritic cells and cell therapy. Cytokin Cell Mol Ther 1997; 3:187-96.
167. Reid CDL, Stackpole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992; 149:2681-8.
168. Caux C, Dezutter-Dambuyant C, Schmitt D, Bancherau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360:258-61.
169. Romani N, GrunerS, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
170. Siena S, Di Nicola M, Bregni M, et al. Massive ex-vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995; 23:1463-71.
171. Szabolcs P, Moore MAS, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 1995; 154:5851-61.
172. Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever JR. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995; 55:1099-104.
173. Mackensen A, Herbst B, Kohler G, et al. Delineation of the dendritic cell lineage by generation of large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitors cells in vitro. Blood 1995; 86:2699-707.
174. Rosenzwajg M, Canque B, Gluckman JC. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood 1996; 87:535-44.
175. Fisch P, Kohler G, Garbe A, et al. Generation of antigen-presenting cells for soluble protein antigens ex-vivo from peripheral blood CD34+ hematopoietic
176. Szabolcs P, Avigan D, Gezelter S, et al. Dendritic cells and macrophages can mature independently from a human bone marrow derived post-colony-forming unit intermediate. Blood 1996; 87:4520-30.
177. Mortarini R, Di Nicola M, Siena S, et al. Cytokine requirements for eliciting melanoma specific cytotoxic T lymphocytes by melanoma antigen peptides loaded on CD34+ cell-derived versus monocyte-derived autologous dendritic cells. Haematologica 1996; 81 (suppl. to 5):83.
178. Mortarini R, Anichini A, Di Nicola M, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen presenting cells in the induction of Melan-A/MART-127-35-specific cytotoxic T-lymphocytes from peripheral blood lymphocytes of melanoma patients with low frequency of cytotoxic T-lymphocyte precursors. Cancer Res 1998; in press.
179. Thurner M, Papesh C, Ramoner R, et al. In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp Hematol 1997; 25:232-7.
180. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is mantained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down regulated by tumor necrosis-α. J Exp Med 1994; 179:1109-18.
181. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in-situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92:8078-82.
182. Hu X, Chakraborty NG, Sporn JR. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56:2479-83.
183. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4:328-32.
184. Porgador A, Gilboa E. Bone marrow generated dendritic cells pulsed a class I-restricted peptide are potent inducers of cytotoxic T-lymphocytes. J Exp Med 1995; 182:255-60.
185. Strobl H, Riedl E, Scheinecker C, et al. TGF-β1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 1996; 157:1499-507.
186. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336:1290-7.
187. Siena S, Di Nicola M, Mortarini R, et al. Expansion of immunostimulatory dendritic cells from peripheral blood of patients with cancer. The Oncologist 1997; 2:65-9.
188. Ratta M, Rondelli D, Fortuna A, et al. Generation and functional characterization of human dendritic cells derived from CD34+ cells mobilized into peripheral blood: Comparison with bone marrow CD34+ cells. Br J Haematol 1998; in press.
189. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196:137-51.
190. Grabbe S, Beissert S, Schwarz T, Gransetin RD. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 1995; 16:1117-21.
191. Knight SC. Dendritic cells as initiators of tumor immunity. Immunol Today 1995; 16:547.
192. Nagata S. Fas ligand and immune evasion. Nature Med 1996; 2:1306-7.
193. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996; 2:1096-103.
194. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. 1. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996; 170:101-10.
195. Gabrilovich DI, Nadaf S, Corak J. Dendritic cells in antitumor immune responses. 2. Dendritic cells grown from bone marrow precursors, but not mature DCs from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170:111-9.
196. Steptoe RJ, Thomson AW. Dendritic cells and tolerance induction. Exp Immunol 1996; 105:397-402.
197. Finkelman FD, Lees AL, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic orimmunogenic fashion. J Immunol 1996; 157:1406-14.
198. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991; 146:3656-61.
199. Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, Mul JJ. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Cancer 1994; 24:315-9.
200. Flamand V, Sornasse T, Demanet C, et al. Murine dendritic cells pulsed in-vitro with tumor antigen induce tumor resistance in-viyo. Eur J Immunol 1994; 24:605-10.
201. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995; 12: 1297-302.
202. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide pulsed dendritic cells induce antigen-speciifc, CTL-mediated protective tumor immunity. J Exp Med 1996; 183:283-7.
203. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J Exp Med 1996; 183:317-22.
204. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5.
205. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996; 184:1953-62.
206. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Med 1997; 6:625-31.
207. Chen W, Peace DJ, Rovira DK, You S, Cheever MA. T cell immunity to the joining region of p210 bcr-abl protein. Proc Natl Acad Sci USA 1992; 89:1468-73.
208. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85:2680.
209. Greco G, Fruci D, Accapezzato D, et al. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10:693-9.
210. Mannering SI, McKenzie JL, Fearnley DB, Hart DNJ. HLA-DR1-Restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997; 90:290-7.
211. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogeneous leukemia. Blood 1997; 89:1133-42.
212. Dermine S, Bertazzoli C, Marchesi E, et al. Lack of T-cell mediated recognition of the fusion region of the pml/RAR-α hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996; 2:593.
213. Henderson RA, Nimgaonkar MT, Watkins SC, Finn O: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996; 56:3763-70.
214. Aicher A, Westermann J, Cayeux S, et al. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene modified antigen presenting cells. Exp Hematol 1997; 25:39-44.
215. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 1997; 5:558-61.